MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up

Merck reported Q3 2026 adjusted EPS of $2.49 versus $2.12 expected and revenue of $18.09B versus $17.23B expected; revenue grew 5% year over year reported (4% excluding FX). It raised 2026 adjusted EPS guidance to $2.77–$2.82 from $2.66–$2.76 and lifted the lower end of sales guidance to $66.8B from $66.3B. Keytruda sales rose 6% to $8.60B, while generic competition pressured Januvia/Janumet and Bridion; Merck shares rose in premarket trading, with no move magnitude stated.

Analysis

The quality of the guidance raise matters more than its headline size: the sales range only lifts at the low end, while the EPS increase is supported in part by a lower tax-rate assumption even as operating-expense guidance rises. That makes the revision less purely commercial than the share reaction may imply. Track organic operating profit and tax assumptions separately in coming quarters.

The growth mix is also less clean than launch growth rates suggest. Keytruda remains a large earnings anchor, while Qlex may defend convenience and access but could shift sales between formulations; verify incremental patient uptake and net economics before treating its contribution as wholly additive. Enflonsia’s seasonal demand and inventory buildup, plus favorable Gardasil public-sector purchasing, create potential reversals in quarterly comparisons. Meanwhile, Januvia/Janumet and Bridion show that generic erosion can overwhelm smaller launches.

Near term, the raised outlook and broad product momentum support sentiment, but substantial prior share outperformance raises the bar for further upside. Over 1–3 months, watch launch persistence, inventory normalization and whether higher R&D/SG&A converts into durable growth. Over 6–18 months, pipeline milestones may diversify the franchise, but the FDA decision is distant and the melanoma combination data do not yet establish near-term revenue. The main contrarian point: the EPS beat may overstate underlying operating leverage; the tax benefit and purchasing timing deserve a discount until confirmed.

Key Decisions for Investors

• Avoid chasing MRK after the initial reaction; consider trimming into strength or maintaining a neutral stance until subsequent results demonstrate that organic operating profit is keeping pace with EPS guidance. Thesis weakens if guidance is lifted again on product demand while expense growth moderates.
• Set a 1–3 month watch on quarterly demand and inventory for Enflonsia and Gardasil, and on U.S. uptake of Winrevair and Qlex. A post-seasonal or purchasing-pattern reversal would challenge the launch-led growth narrative; sustained end-market demand would support it.
• Do not short AZN on the reported Lynparza decline alone: the article gives no evidence that this alliance revenue movement materially changes AZN’s consolidated outlook. Reassess only with corroborating portfolio-level guidance or earnings evidence.
• Treat Moderna’s melanoma-combination data as a longer-dated optionality catalyst, not a near-term earnings driver. Verify regulatory and commercialization milestones before assigning material value to the collaboration.